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Recently, eicosanoid-lysophospholipids were identified as
novel metabolites generated from the direct cyclooxygenase- or
lipoxygenase-catalyzed oxidation of 2-arachidonoyl-lysophos-
pholipids produced from either phospholipase A1-mediated hy-
drolysis of diacyl arachidonoyl-phospholipids or through the
cytochrome c-catalyzed oxidative hydrolysis of the vinyl ether
linkage of arachidonoyl-plasmalogens. Although the metabolic
pathways generating eicosanoid-lysophospholipids have been
increasingly appreciated, the signaling functions of eicosanoid-
lysophospholipids remain largely unknown. Herein, we demon-
strate that 2-12(S)-HETE-lysophospholipids as well as nones-
terified 12(S)-HETE are potent lipid mediators that activate
THP-1 human monocytic cells to generate tumor necrosis fac-
tora (TNFa) and interleukin 8 (IL8). Remarkably, low nanomo-
lar concentrations of 12(S)-HETE-lysophospholipids, but not
other oxidized signaling lipids examined activated THP-1 cells
resulting in the production of large amounts of TNFa. More-
over, TNFa release induced by 12(S)-HETE-lysophospholipids
was inhibited by the TNFa converting enzyme inhibitor TAPI-0
indicating normal processing of TNFa in THP-1 cells stimulated
with these agonists. Western blotting analyses revealed that 12
(S)-HETE-lysophospholipids activated the phosphorylation of
NFkB p65, suggesting activation of the canonical NFkB signaling
pathway. Importantly, activation of THP-1 cells to release TNFa
was stereoselective with 12(S)-HETE favored over 12(R)-HETE.
Furthermore, the EC50 of 2-12(S)-HETE-lysophosphatidylcholine
in activating THP-1 cells was 2.1 nM, whereas the EC50 of free 12
(S)-HETE was 23 nM. Additionally, lipid extracts of activated pla-
telets were separated by RP-HPLC demonstrating the coelution
of 12(S)-HETE with fractions initiating TNFa release. Collec-
tively, these results demonstrate the potent signaling proper-
ties of 2-12(S)-HETE-lysophospholipids and 12(S)-HETE by
their ability to release TNFa and activate NFkB signaling
thereby revealing a previously unknown role of 2-12(S)-HETE-
lysophospholipids inmediating inflammatory responses.
Oxidized lipid second messengers are of critical importance
for the homeostatic regulation of multiple physiologic func-
tions that are cell type and context dependent (e.g. arthritis,
cancer, and cardiovascular disease) (1–4). The biosynthesis of
inflammatory lipid mediators, such as prostaglandins, and hy-
droxyeicosatetraenoic acids (HETEs) are crucial for the initia-
tion and amplification of inflammatory processes (5, 6). Specific
molecular species of proinflammatory lipid mediators have dis-
tinct functions during both the acute phase of the inflammatory
response and during its chronic evolution. The canonical path-
way for the generation of lipid second messengers is through
the regiospecific sn-2 hydrolysis of arachidonate-containing
phospholipids by phospholipases A2, which can be activated
within seconds during elevation of cellular calcium ion concen-
trations. This results in the release of nonesterified arachidonic
acid (AA) and lysophospholipids (7–11). The released AA is rap-
idly oxidized by a plethora of intracellular oxidases (e.g. cyclooxy-
genases, lipoxygenases, or cytochromes P450) generating a
diverse array of potent signaling molecules (12–16). In contrast,
the production of protein inflammatory mediators, such as
cytokines, are typically transcriptionally regulated which often
requires hours to generate a robust cellular response (17).
Proinflammatory cytokines comprise an extensively charac-
terized class of protein-based modulators of inflammation that
are critical participants in inflammation and the immune
response (18–20). During bacterial infection, the production of
proinflammatory cytokines is activated by bacterial products,
such as lipopolysaccharides, lipoproteins, and dsRNA (21–23).
These responses are mediated by Toll-like receptors, and
distinct endotoxins that serve as ligands for different Toll-like
receptors (24). Proinflammatory cytokines have multiple
functions that work in concert to facilitate an inflammatory
response. In most cases, the inflammatory response is appro-
priate to combat the infection. However, an excessive response
results in chronic inappropriate inflammation that can damage
cells and compromise the function of specific organs.
Cytokines and oxidized fatty acids also play pivotal roles in
the resolution of inflammation. Anti-inflammatory cytokines
primarily function by inhibiting the synthesis of IL1, TNFa,
and other major proinflammatory cytokines (25). IL10 is the
most important anti-inflammatory cytokine in the human
immune system. IL10 is a very potent inhibitor ofmonocyte/mac-
rophage cytokine synthesis includingTNFa, IL-1, IL-6, IL-8, IL-12,
granulocyte colony-stimulating factor, MIP-1a, and MIP-2a (26–
28). In addition to IL10, IL1ra, IL4, IL6, IL11, IL13, and TGFb also
have anti-inflammatory activities (25). The metabolites of docosa-
hexaenoic acid and eicosapentaenoic acid (e.g. resolvins and pro-
tectins) are the major lipid mediators that function in the resolu-
tion of inflammation (29, 30). Resolvin E1 (RvE1) can inhibit the
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infiltration of polymorphonuclear leukocytes at nanomolar con-
centrations (31). RvE1 also can stimulate the macrophage-medi-
ated phagocytosis of apoptotic polymorphonuclear leukocytes
(32), inhibit dendritic cell migration and cytokine release (33), and
up-regulate CCR5 expression in leukocytes (34).
Previously, we discovered that calcium-independent phos-
pholipase A2g (iPLA2g, also known as PNPLA8) is predo-
minantly an sn-1 lipase for phospholipids containing a polyun-
saturated fatty acyl chain at the sn-2 position generating
2-arachidonoyl-lysophospholipids (35). Remarkably, we found
that 2-eicosanoid-lysophospholipids including 12(S)-HETE-, 15
(S)-HETE-, 11-HETE-, and PGE2-lysophospholipids have emerged
as novel lipid natural products that are synthesized through direct
oxidation of 2-arachidonoyl-lysophospholipids by 12-lipoxygen-
ase (12-LOX), 15-lipoxygenase (15-LOX), and cyclooxygenase-2
(COX2) (36, 37). The discovery of the ability of cellular oxidases
to oxidize lysophospholipids containing polyunsaturated fatty
acids suggested a previously unknown pathway for the synthesis
of novel lipid metabolites that could potentially serve as novel
effectors of specific biologic signaling processes. Additionally, we
demonstrated that eicosanoid-lysophospholipids could serve as
effective substrates for cPLA2a thereby contributing to the
release of nonesterified eicosanoids (36). Furthermore, we have
recently demonstrated that eicosanoid-lysophos-pholipids could
be acylated by a microsomal sn-1 acyltransferase activity resulting
in the production of oxidized phospholipids that have been sug-
gested to serve as damage associated molecular patterns that have
potent effects on multiple cellular processes (38). The scope of the
significance of these recently identified oxidized lysophospholipid
metabolites, their pathways of synthesis, and their potential signal-
ing properties are only now beginning to be explored.
Herein, we report that 12-LOX–generated products of ara-
chidonic acid and arachidonoyl-lysophospholipids (i.e. 12(S)-
HETE-lysophospholipids, 12(S)-HETE, and their correspond-
ing hydroperoxides) can induce the release of TNFa and IL8
from THP-1 human monocytic cells. We provide further evi-
dence that 12(S)-HETE-lysophospholipid–induced release of
mature cleaved TNFa is mediated by TNFa converting enzyme
(TACE), which can be inhibited by its inhibitor TAPI-0. Further-
more, we identify the stereoselectivity of 12(S)-HETE versus 12
(R)-HETE in the activation of THP-1 cells, suggesting that 12(S)-
HETE induced signaling processes are due to specific ligand-re-
ceptor interactions. In addition, we show that the NFkB pathway
is activated by 12(S)-HETE-lysophospholipids. Collectively, these
results demonstrate the signaling properties and underlying
mechanisms of 12(S)-HETE-lysophospholipid- and 12(S)-HETE-
induced TNFa release fromTHP-1 cells and identify a previously
uncharacterized role of oxidized lysophospholipids in activating
immune cells promoting inflammatory cascades.
Results
Stimulation of THP-1 cells with 12-LOX–generated
metabolites of arachidonoyl-lysophospholipids and
arachidonic acid induce the release of TNFa
To determine the effect of various oxidized lipids in activating
THP-1 cells, purified individual oxidized lipids of interest includ-
ing HETEs, epoxyeicosatrienoic acids (EETs), oxidized lysophos-
pholipids, as well as nonoxidized lipids, including arachidonoyl-
lysophospholipids, arachidonic acid, or oleic acid (each at 200 nM
concentration), were incubated with THP-1 cells grown in sus-
pension. After 1 h of incubation, the cells were pelleted by centrif-
ugation, and the amount of TNFa in the supernatant was quanti-
fied by ELISA. Notably, THP-1 cells released considerable
amounts of TNFa in response to 2-12(S)-HETE-lysophospholi-
pids (i.e. 2-12(S)-HETE-lysophosphatidylcholine and 2-12(S)-
HETE-lysophosphatidylethanolamine) as well as nonesterified 12
(S)-HETE, but not by other oxidized lipids nor non-oxidized fatty
acids (Fig. 1). It is intriguing that 11(S)-HETE also induced the
release of TNFa, although not as robustly as 12(S)-HETE, indicat-
ing that the position of the hydroxy group on the fatty acyl chain is
critical to the signaling process(es)mediating TNFa release.
12-LOX catalyzes the stereospecific oxidation of AA to gen-
erate 12(S)-HpETE, which is readily converted to 12(S)-HETE
by cellular peroxidases (39, 40). Recently, we have demon-
strated that 2-arachidonoyl-lysophospholipids are excellent
substrates for 12-LOX to generate 2-12(S)-HpETE-lysophospho-
lipids, which are similarly converted to 2-12(S)-HETE-lysophos-
pholipids (37). In addition, because lysophospholipids exist as
one of either two regioisomers (i.e. 1-acyl-lysophospholipid or 2-
acyl-lysophospholipid) that can be interconverted by internal
acyl-migration, we tested each regioisomer of 12(S)-H(p)ETE-
LPC, 12(S)-H(p)ETE-LPE, 15(S)-H(p)ETE-LPC, and 15(S)-H(p)
ETE-LPE (i.e. sn-1 versus sn-2). Accordingly, THP-1 cells were
incubated with 200 nM of the purified 12-LOX– or 15-LOX–gen-
erated 1-eicosanoid- or 2-eicosanoid-lysophospholipids (both
hydroxy and hydroperoxyl derivatives) (Fig. S1) prior to quantify-
ing the amount of TNFa released from the cells by ELISA. The
results indicated that both regioisomers (sn-1 and sn-2) of 12(S)-
HETE-lysophospholipids and 12(S)-HpETE-lysophospholipids
are equally potent inmediating the release of TNFa. In stark con-
trast, despite their close structural similarity to the 12-LOX–
derived eicosanoid-lysophospholipids, 15(S)-HpETE-lysophospho-
lipids and 15(S)-HETE-lysophospholipid regioisomers as well as
nonesterified 15(S)-HpETE were ineffective in promoting the
release of TNFa fromTHP-1 cells under the conditions examined.
To determine whether the observed TNFa release was due
to cell injury or cell death, lactate dehydrogenase (LDH) activity
in the media was used as a marker for cell injury/death. Incuba-
tion of the cells for 1 h with 12(S)-HETE or 2-12(S)-HETE-LPC
did not inducemeasurable LDH release from THP-1 cells, indi-
cating TNFa release is not due to cell death or injury (Fig. 1B).
To determine whether the increase in TNFa release was regu-
lated by increased mRNA expression, TNFa mRNA was quanti-
fied in the THP-1 cells after incubation with 12(S)-HETE or 2-12
(S)-HETE-LPC. As shown in Fig. S2, 40 min or 2 h of incubation
with 12(S)-HETE or 2-12(S)-HETE-LPC did not significantly
increase the expression of TNFa mRNA, indicating that TNFa
release under these conditions is not transcriptionally regulated.
Screening of proinflammatory cytokines released by THP-1
cells after incubation with 2-12(S)-HETE-
lysophosphatidylcholine (2-12(S)-HETE-LPC)
Next, to determine whether 12(S)-HETE-lysophospholipids
could induce the release of other proinflammatory cytokines, a
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panel of cytokines was examined including interferon g (IFNg),
interleukins (ILs), and granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) by an ELISA array. Similar to TNFa,
increased amounts of IL8 were also secreted by THP-1 cells af-
ter treatment with 200 nM 2-12(S)-HETE-lysophosphatidylcho-
line (Fig. 2). Significant increases in 12(S)-HETE-LPC induced
release of other proinflammatory cytokines were not observed
under the conditions employed.
Dose-response profiles of 12(S)-HETE-lysophospholipids and
12-HETE–mediated activation of THP-1 cells to release TNFa
To determine the relative potencies of the two regioisomers
(1-acyl- versus 2-acyl-) of 12(S)-HETE-LPC and the stereoiso-
mers of 12-HETE that mediate the activation THP-1 cells to
release TNFa, various concentrations of 1-12(S)-HETE-
LPC, 2-12(S)-HETE-LPC, 12(S)-HETE, and 12(R)-HETE were
administered to THP-1 cells for 1 h and the amount of TNFa in
the media was analyzed by ELISA (Fig. 3). Overall, the oxidized
lysophospholipids have 10-fold higher potency (i.e. lower EC50
values) than the nonesterified oxidized fatty acids examined
(Table 1). No significant differences in EC50 values for the
release of TNFa were observed between 1-12(S)-HETE-LPC
and 2-12(S)-HETE-LPC (Table 1).
Comparisons of the dose-response profiles revealed the abil-
ity of 12(S)-HETE to induce the release of TNFa from THP-1
cells at lower effective concentrations than 12(R)-HETE.
Because 12(S)-HETE is the naturally occurring stereoisomer
generated by 12-LOX (also known as ALOX12), the stereose-
lectivity of 12(S)-HETE in the activation of THP-1 cells sug-
gests that this process is mediated by a specific ligand-receptor
interaction rather than by nonspecific effects of fatty acids or
oxidized lysophospholipids onmembrane dynamics.
Temporal dependence of 12(S)-HETE-lysophospholipid
induced release of TNFa
To determine the temporal dependence of TNFa secretion
induced by 12-LOX–generated eicosanoid-lysophospholipids,
either 2-12(S)-HETE-lysophospholipids or 2-12(S)-HpETE-
lysophospholipids were incubated with THP-1 cells for up to 2
h followed by measurement of TNFa present in the media by
ELISA. As shown in Fig. 4A, the majority of TNFa was released
after 1 h incubation with 10 nM 2-12(S)-HETE-LPC, 2-12(S)-
HpETE-LPC, 2-12(S)-HETE-LPE, or 2-12(S)-HpETE-LPE with
negligible additional TNFa release after a 2 h incubation. The
temporal course of TNFa release activated by these 12-
LOX–generated eicosanoid-lysophospholipid products were
Figure 1. 12(S)-HETE-lysophospholipids and 12(S)-HETE activate THP-1 cells to release TNFa. After 4 h incubation in serum-free RPMI 1640 media at
37 °C under a 5% CO2 atmosphere, serum-starved THP-1 cells (13 10
6 cells/ml) were treated with the indicated lipids (200 nM, delivered in dimethyl sulfoxide
(DMSO)) or DMSO vehicle alone as control (0.1% v/v) and incubated for 1 h under the same conditions, followed by centrifugation of the cell suspension at
2003 g for 3 min. The TNFa present in the supernatant was quantified by ELISA as described under “Experimental procedures” (A). The cytotoxicity of 12(S)-
HETE and 2-12(S)-HETE-LPC were evaluated by measuring the lactate dehydrogenase activity in the supernatant (B). 1% Triton X-100 was used as a positive
control for the LDH assay. Values are the average of four independent preparations. Error bars represent S.D.
Figure 2. 2-12(S)-HETE-lysophosphatidylcholine activates THP-1 cells to release proinflammatory cytokines. After 4 h incubation in serum-free RPMI
1640media at 37 °C under a 5% CO2 atmosphere, serum-starved THP-1 cells (13 10
6 cells/ml) were activated by 200 nM 2-12(S)-HETE-lysophosphatidylcholine
for 1 h under the same conditions in comparison to DMSO vehicle alone (Control). Proinflammatory cytokines present in the supernatant were analyzed by a
Multianalyte ELISA Array Kit as described under “Experimental procedures.” *, p, 0.05; **, p, 0.01. Values are the average of four independent preparations.
Error bars represent S.D.
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indistinguishable. In comparison, TNFa secretion activated by
10 ng/ml of lipopolysaccharide (LPS) continued to increase af-
ter 1 h, which contrasts with that observed with the tested oxi-
dized lysophospholipids (Fig. 4B). We note that the amount of
TNFa released in the presence of 2-12(S)-HETE-lysophospho-
lipids after 1 h incubation was ;10% of the total amount of
TNFa released after stimulation by 10 ng/ml of LPS.
In addition, we tested TNFa secretion fromTHP-1 cells after
24 h incubation with either 12(S)-HETE-LPC or 12(S)-HETE.
As shown in Fig. 4C, after 24 h incubation, the level of TNFa in
the cell media of all tested samples returned to baseline. Results
in Fig. 4, A and C, demonstrated that TNFa levels reached a
maximum after 1-2 h incubation with 12(S)-HETE or 12(S)-
HETE-LPC, and then decayed to background levels thereafter.
We also tested IL1b secretion from THP-1 cells after 24 h incu-
bation with 12(S)-HETE-LPC or 12(S)-HETE. As shown in Fig.
4D, there was no detectable IL1b secretion from THP-1 cells
even after 24 h incubation with 12(S)-HETE or 12(S)-HETE-
LPC. Collectively, these results demonstrate that 12(S)-HETE-
lysophospholipids are potent (low nM) stimulators of THP-1
cells, which can rapidly induce (,1 h) the release of TNFa.
2-12(S)-HETE- and 2-12(S)-HpETE-lysophospholipid–induced
TNFa secretion is mediated by TACE
The secretion of TNFa from immune cells in response to
inflammatory stimuli is mediated by the cleavage of the mem-
brane form of TNFa (25 kDa) by TACE, releasing the soluble
form of TNFa (18 kDa). To determine whether 12(S)-HETE-
lysophospholipid-induced release of TNFa is mediated by
TACE, THP-1 cells were preincubated with 1 or 5 mM TAPI-0,
a specific TACE inhibitor, prior to treatment with 2-12(S)-
HETE-LPC, 2-12(S)-HpETE-LPC, 2-12(S)-HETE-LPE, or 2-12
(S)-HpETE-LPE. Pretreatment of THP-1 cells with 1 or 5 mM
TAPI-0 substantially decreased TNFa release induced by 12-
LOX–generated eicosanoid-lysophospholipids indicating the
role of TACE in the processing and secretion of TNFa from
THP-1 cells treated with 12(S)-HETE- or 12(S)-HpETE-lyso-
phospholipids (Fig. 5).
12(S)-HETE- and 12(S)-HpETE-lysophospholipids induce
production of the membrane-bound form of TNFa in THP-1
cells
To substantiate the expression level of the membrane-bound
form of TNFa after stimulation with 12-LOX–generated eicosa-
noid-lysophospholipids, THP-1 cells were treated with various
non-oxidized lipids or 12-LOX–generated metabolites (Fig. 6).
After 1 h of incubation at 37 °C, THP-1 cells were centrifuged,
and the cell pellets were resuspended in lysis buffer for Western
blotting analysis of the soluble and membrane forms of TNFa.
Incubation of THP-1 cells with 10 nM 12(S)-HETE-lysophospho-
lipids, 12(S)-HpETE-lysophospholipids, or nonesterified 12(S)-
HETE resulted in a significant increase in the level of the mem-
brane form TNFa (25 kDa) as well as its active proteolytic prod-
uct, TNFa (18 kDa). In sharp contrast, non-oxidized 2-arachido-
noyl-lysophospholipids or free arachidonic acid did not affect the
protein expression level of themembrane form of TNFa (Fig. 6).
12(S)-HETE- and 12(S)-HpETE-lysophospholipids activate the
nuclear factor kB (NFkB) pathway in THP-1 cells
The transcription factor NFkB serves as a central mediator
in many inflammatory responses (41). The activation of the
NFkB pathway induces the expression of multiple proinflam-
matory genes including cytokines and chemokines, as well as
regulation of the inflammasome (42). In addition, NFkB plays a
critical role in determining cell survival and the activation or
differentiation of innate immune cells (43, 44). To determine
whether the NFkB pathway is activated by 2-12(S)-HETE-lyso-
phospholipids or 12(S)-HETE, the relative contents of phos-
pho-NFkB p65 and phospho-IkB in control and stimulated
THP-1 cells were determined by Western blotting analysis. In
the presence of 10 nM 2-12(S)-HETE-lysophospholipids or 2-12
(S)-HpETE-lysophospholipids, the phosphorylation of NFkB
p65 is substantially increased, indicating activation and nuclear
translocation of NFkB (Fig. 7A). Compared with the tested oxi-
dized lysophospholipids, 10 nM nonesterified 12(S)-HETE and
12(S)-HpETE are less potent in activating the phosphorylation
of NFkB p65 or IkB, whereas non-oxidized arachidonoyl-lyso-
phospholipids or arachidonic acid did not have any measurable
effect on NFkB p65 or ikB phosphorylation.
To substantiate the difference between 10 nM 2-12(S)-
HETE-LPC and 10 nM 12(S)-HETE in activating THP-1 cells,
10 nM 2-12(S)-HETE-LPC, 10 nM 12(S)-HETE, or DMSO con-
trol (0.1%, v/v) were incubated with THP-1 cells in triplicate.
The cells were pelleted, lysed, and the phosphorylation of
NFkB p65 was analyzed by Western blotting analysis. The
results show that 10 nM 2-12(S)-HETE-LPC induces greater
overall phosphorylation of NFkB p65 (normalized tob-tubulin)
compared with 10 nM 12(S)-HETE, indicating that 12(S)-
HETE-LPC is more potent in activating THP-1 cells compared
with nonesterified 12(S)-HETE (Fig. 7, C and D). Collectively,
these results demonstrate that 12(S)-HETE- and 12(S)-
HpETE-lysophospholipids activate the canonical NFkB
Figure 3. Dose-response profile for 12(S)-HETE-lysophospholipids and
nonesterified 12-HETE–mediated activation of THP-1 cells to release
TNFa. After 4 h of incubation in serum-free RPMI 1640 media at 37 °C under
a 5% CO2 atmosphere, serum-starved THP-1 cells (1 3 10
6 cells/ml) were
treated with 200 nM, 20 nM, 2 nM, 200 pM, 20 pM, 2 pM 1-12(S)HETE-LPC or 2-
12(S)HETE-LPC, or 1mM, 100 nM, 10 nM, 1 nM, 100 pM, 10 pM 12(S)HETE or 12(R)
HETE. After 1 h of incubation under the same conditions, the samples were
centrifuged at 2003 g for 3 min, and the amount of TNFa present in the su-
pernatant was determined by ELISA as described under “Experimental proce-
dures.” Values are the average of three independent preparations. Error bars
represent S.D.
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signaling pathway for the transcriptional regulation of
inflammatory responses in immune cells.
Activation of THP-1 cells by 12(S)-HETE produced by
thrombin-activated platelets
In addition to testing various known oxidized signaling
lipids (including HETEs, EETs, HETE-lysophospholipids, and
HpETE-lysophospholipids), we sought to identify other poten-
tially unknown oxidized lipid mediators capable of activating
THP-1 cells. Because activated platelets are a well-established
source of eicosanoids and other potent oxidized lipidmediators
of inflammation (45, 46), we treated isolated mouse platelets
with thrombin, extracted lipids from the thrombin-activated
platelets, and resolved the extracted lipids on a C18 HPLC col-
umn (Fig. 8A). Separate eluent fractions were then collected,
dried under nitrogen stream, resuspended in serum-freemedia,
and incubated with THP-1 cells. Of the tested fractions, only
fraction 4 from the HPLC-separated lipid extract of thrombin-
activated platelets was able to appreciably stimulate THP-1
cells to release TNFa (Fig. 8C). Next, fraction 4 from the first
purification step was further fractionated (resolved) by collect-
ing smaller volume fractions of the column eluent (Fig. 8B).
These eluent fractions were then dried, resuspended in serum-
free media, and incubated with THP-1 cells. As shown in Fig.
8D, only fractions 4-5 and 4-6 were capable of activating THP-
1 cells to release TNFa.
To identify themolecule(s) in fraction 4-5 responsible for the
activation of THP-1 cells, the lipids in fraction 4-5 were ana-
lyzed by LC–MS. It was demonstrated that 12(S)-HETE is the
major species in this fraction (Fig. 8E). The identity of 12(S)-
HETE was substantiated by N-(4-aminomethylphenyl)-pyri-
dinium (AMPP) derivatization and comparison of the obtained
tandem mass spectra with a commercial 12(S)-HETE standard
(Fig. 8F). Next, the 12(S)-HETE content in each fraction was
analyzed by LC-MS/MS, which showed that only fraction 4
(from the initial purification), fraction 4-5, and fraction-4-6
(further resolved fractions from fraction 4) contained 12(S)-
Figure 4. Time-dependent release of TNFa from THP-1 cells activated by
12(S)-H(p)ETE-lysophospholipids or 12(S)-HETE. THP-1 cells (13 106 cells/ml)
were serum-starved in serum-free RPMI 1640 media for 4 h at 37 °C under a 5%
CO2 atmosphere prior to incubation with the indicated oxidized-lysophospholi-
pids (10 nM each) (A) or 10 ng/ml of O55:B5 Escherichia coli LPS (B) for 0.5, 1, or 2
h. DMSO vehicle alone (0.1% v/v) served as control for each experiment. After
incubation, the samples were centrifuged at 2003 g for 3 min, and the amount
of TNFa in the supernatantwas determined by ELISA as described under “Experi-
mental procedures.” Cells were also incubated with the indicated oxidized lipids
for 24 h prior to measurement of TNFa (C) and IL1b (D) by ELISA. Values are the
average of four independent preparations. Error bars represent S.D.
Figure 5. 12(S)-HETE-lysophospholipid–induced release of TNFa is
mediated by TACE. THP-1 cells (13 106 cells/ml) were serum-starved in se-
rum-free RPMI 1640 media for 4 h at 37 °C under a 5% CO2 atmosphere prior
to incubation with the indicated oxidized lysophospholipids (10 nM each) or
DMSO vehicle (0.1%, v/v) alone as control in the absence or presence of dif-
ferent concentrations of the TACE inhibitor TAPI-0. After 1 h of incubation
under the same conditions, the samples were centrifuged at 200 3 g for 3
min and the TNFa present in the supernatant was quantified by ELISA as
described under “Experimental procedures.” Values are the average of four
independent preparations. Error bars represent S.D.
Table 1
Half-maximal effective concentrations (EC50) of 12(S)-HETE-lysophosphatidylcholine regioisomers and 12-HETE in activating THP-1 cells to
release TNFa
The data from Fig. 3 were analyzed by nonlinear regression and the EC50 values were determined as described under “Experimental procedures.”
Agonist 12(S)-HETE 12(R)-HETE 2-12(S)-HETE-LPC 1-12(S)-HETE-LPC
EC50 (best fit) 22 nM 65 nM 2.3 nM 3.2 nM
EC50 (95% confidence interval) 14-34 nM 36-112 nM 1.5-3.5 nM 1.9-5.6 nM
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Figure 6. 12(S)-HETE-lysophospholipid–induced production of themembrane–associated form of TNFa and the soluble form of TNFa protein. THP-
1 cells (13 106 cells/ml) were serum-starved in serum-free RPMI 1640 media for 4 h at 37 °C under a 5% CO2 atmosphere prior to treatment with the indicated
lipids or oxidized lysophospholipids (10 nM each) or DMSO vehicle alone (0.1%, v/v) as control. After 1 h of incubation under the same conditions, the samples
were centrifuged at 2003 g for 3 min. The resultant cell pellets were lysed in cell lysis buffer. Proteins in the cell lysates were separated by SDS-PAGE and the
amount of TNFa (25-kDa membrane associated and 18-kDa soluble forms) present in each sample were determined byWestern blotting analysis as described
under “Experimental procedures.” The same blot was probed with an antibody against b-tubulin, which served as a loading control.
Figure 7. 12(S)-HETE-lysophospholipids activate the NFkB pathway in THP-1 cells. THP-1 cells (13 106 cells/ml) were serum-starved in serum-free RPMI
1640 media for 4 h at 37 °C under a 5% CO2 atmosphere prior to treatment with the indicated lipids or oxidized lysophospholipids (10 nM each) or DMSO vehi-
cle alone (0.1% v/v). After 1 h of incubation under the same conditions, the cell suspensions were centrifuged at 2003 g for 3 min. The cell pellets were then
lysed in cell lysis buffer prior to separation of cellular proteins by SDS-PAGE and transfer to a PVDF membrane. A, phospho-NFkB p65, phospho-IkB, and
b-tubulin were probed byWestern blotting as described under “Experimental procedures.” B, densitometric quantitation of NFkB p65 phosphorylation based
on the blot shown in panel A. C, comparison of NFkB p65 phosphorylation in cells treated with DMSO, nonesterified 12(S)-HETE, or 2-12(S)-HETE-LPC per-
formed in triplicate. D, densitometric quantitation of NFkB p65 phosphorylation based on the blot shown in panel C. *, p, 0.05; **, p, 0.01. The correspond-
ing blots were probed with an antibody against b-tubulin, which served as a loading control. In panel C, values are the average of three independent
preparations. Error bars represent S.D.
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HETE (Fig. 8,G andH), which is consistent with the ability of
these C18 HPLC fractions to activate THP-1 cells to release
TNFa.
The distribution of 12(S)-HETE or 12(S)-HETE-lysophos-
pholipids is likely cell-type and context dependent. 12(S)-
HETE is the major eicosanoid product in activated platelets
because platelets have high levels of cPLA2a, 12-lipoxygenase,
and relatively low levels of iPLA2g (39). Furthermore, the lyso-
phospholipase activity of cPLA2a is higher than its phospholi-
pase activity. Thus, even if lysolipids were produced, it is
unlikely they would be observed because cPLA2a is an excellent
sn-2 acyl lysophospholipase (47) and the lysophospholipid
product would likely be hydrolyzed before it can accumulate
(47, 48). Collectively, these results demonstrate that 12(S)-
HETE is the major proinflammatory lipid mediator produced
by thrombin-activated platelets that can stimulate THP-1 cells
to release TNFa.
Discussion
In this study, we report that 12(S)-H(p)ETE-lysophospholi-
pids as well as nonesterified 12(S)-H(p)ETE activate THP-1
cells to release TNFa in a dose- and time-dependent manner.
Importantly, this process is stereoselective and TNFa release is
blocked by pharmacologic inhibition of TACE. Furthermore,
12(S)-H(p)ETE-lysophospholipids and nonesterified 12(S)-
HETE activate the phosphorylation of NFkB p65, indicating
the transcriptional activation of inflammatory programs in
THP-1 cells. Collectively, these findings demonstrate that
12(S)-HETE, 12(S)-HETE-lysophospholipids, and their cor-
responding hydroperoxides are potent lipid agonists that
promote the activation of THP-1 cells to release TNFa and
underscore the importance of specific oxidized lipids as
mediators of inflammation.
Calcium-independent phospholipase A2g (iPLA2g, also
known as PNPLA8) is a critical membrane-associated calcium-
regulated phospholipase known to participate in mitochondrial
signaling and bioenergetics (4, 49). This enzyme has the un-
usual property of catalyzing both sn-1 and sn-2 hydrolysis of
phospholipids containing a saturated or monounsaturated fatty
acyl chain at the sn-2 position. In sharp contrast, when polyun-
saturated aliphatic constituents (e.g. arachidonic acid) are pres-
ent at the sn-2 position, iPLA2g catalyzes the highly regioselec-
tive cleavage of phospholipids at the sn-1 position resulting in
the generation of 2-arachidonoyl-lysophospholipids (35). In
addition, we have demonstrated that cytochrome c can initiate
the oxidative cleavage of the vinyl ether bond in plasmalogens
under oxidative stress, generating 2-arachidonoyl-lysophos-
pholipids and a-hydroxy aldehydes (50). Importantly, the
unanticipated regiospecificity of iPLA2g and plasmalogenase
activity of cytochrome c represent previously unknown conver-
gent metabolic pathways resulting in the generation of 2-AA-
LPC and 2-arachidonoyl-lysophosphatidylethanolamine (2-
AA-LPE), which serve as a central branch point metabolites for
the production of eicosanoid-lysophospholipids by cellular
oxidases.
In previous work, we have demonstrated that 2-arachido-
noyl-lysophospholipids can be directly oxidized by cyclooxy-
genase 2, 12-lipoxygenase, or 15-lipoxygenase, generating
PGE2-lysophospholipids, 12(S)-HpETE-lysophospholipids, or
15(S)-HpETE-lysophospholipids, respectively (36, 37). In this
study, we have demonstrated that 2-12(S)-HETE-lysophospho-
lipids can serve as signaling molecules that induce monocyte
cells to release TNFa and activate the NFkB pathway, indicat-
ing potential signaling functions of eicosanoid-lysophospholi-
pids in inflammation and the immune response. The dose-
response profiles indicate increased affinity of eicosanoid-lyso-
phospholipids to initiate these signaling pathways compared
with their nonesterified counterparts, suggesting the biologic
importance of an iPLA2g/cyt c ! 2-AA-LPC ! 2-12(S)-
HETE-LPC signaling axis as shown in Fig. 9.
It is well-established that cytokines can promote the synthe-
sis of inflammatory lipid mediators through the transcriptional
activation of phospholipases and cyclooxygenase (51). For
example, treatment with IL1 in combination with TNFa results
in the elevated expression of cPLA2a and cyclooxygenase-2,
increasing the production of prostaglandins and HETEs
thereby establishing an autoamplification network that is cell-
specific and context-dependent (51–57). Molina-Holgado et al.
(51) suggested that IL1b-induced PGE2 synthesis is mediated
by PKC andmitogen-activated protein kinases in murine astro-
cytes. Fournier et al. (52) demonstrated the critical function of
cAMP in TNFa-activated PGE2 production in murine macro-
phages. Additionally, Nakao et al. (54) showed that TNFa-
induced PGE2 release in human fibroblasts is controlled by
NFkB.
Lipid second messengers such as prostaglandins and throm-
boxanes typically function by binding to a family of G protein–
coupled receptors, resulting in increased cAMP, calcium flux,
and/or inositol triphosphate concentrations (6). It has also
been demonstrated that lipid second messengers can modulate
the expression of proinflammatory cytokines. For example, it
was previously shown that exogenous PGE2 activated the pro-
duction of IL6 and TNFa in murine peritoneal macrophages
(58, 59).
Previously published work using genetically engineered mice
has suggested the relationship between 12/15-LOX and inflam-
mation. For example, Middleton and co-workers (60) found
that 12/15-LOX–deficient macrophages produced reduced
Figure 8. Activation of TNFa production by lipids extracted from activated platelets.Mouse platelets were isolated and activated by thrombin. After pla-
telet activation, lipids were extracted using chloroform/methanol/water (1:1:1, v/v/v) and purified using C18 HPLC. Eluent fractions of were collected as shown
and used to stimulate THP-1 cells as described under “Experimental procedures.” A, UV absorbance chromatogram of lipid extracts resolved by C18 HPLC from
control and thrombin-activated platelets. Indicated eluent fractions were collected to test their ability to activate THP-1 cell to release TNFa. B, UV absorbance
chromatogram of lipids in fraction 4 with collected subfractions (4-1 through 4-6). C and D, fractions from the first (A) and second (B) purification were dried by
a flow of nitrogen, resuspended in RPMI 1640 media, and incubated with THP-1 cells (13 106 cells/ml) for 1 h. The TNFa released was quantified by ELISA. E
and F, the identity of 12(S)-HETE in fraction 4-5 was confirmed by comparison of extracted ion retention time (E) and MS/MS spectra (F) with authentic 12(S)-
HETE standard as indicated. G and H, 12(S)-HETE in fractions from the first (A) and second (B) purification were quantified by LC-MS/MS. For C, D, G, and H, val-
ues are the average of four independent preparations. Error bars represent S.D.
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levels of cytokines in response of lipopolysaccharide. Addition-
ally, Dioszeghy et al. (61) reported that peritoneal lavage of 12/
15-LOX2/2 mice showed decreased levels of several cytokines
including TNFa, indicating the involvement of 12/15-LOX in
peritoneal macrophage cytokine production. Wen et al. (62)
showed that 12(S)-HETE and 12(S)-HpETE can induce a mild
increase of proinflammatory cytokines’ mRNA in macro-
phages. To the best of our knowledge, there are only a few stud-
ies that have investigated the regulation of proinflammatory
cytokines by 12(S)-HETE and those studies have quantified
cytokine mRNA but not increases in cytokine protein amounts.
The present results demonstrate the regiospecific and stereo-
specific potency of 2-12(S)-HETE-lysophospholipids and 12
(S)-HETE in activating THP-1 cells to synthesize/release
TNFa and IL8 and promote downstream signaling pathways
of inflammation.
At least three different mechanisms for secretion of cyto-
kines have been described in innate immune cells. First, as
expected, cytokine protein synthesis can be controlled by tran-
scriptional increases in cytokine mRNA (63, 64). The transcrip-
tional alterations resulting in cytokine synthesis through this
mechanism usually requires hours for synthesis. Second, many
innate immune cells contain preformed cytokines, which are
stored in secretory vesicles or granules (65–67). These pre-
formed cytokines may be released within minutes upon stimu-
lation along the secretory pathway. The third mechanism
involves translational regulation in which the mRNA encoding
the target protein is present but not translated due to binding
of an inhibitory polynucleotide to the translation initiation site
that can be removed. After cellular activation, the inhibitor
detaches from its cognate mRNA. Cells including macrophages
and dendritic cells do not have typical secretory granules that
can store preformed cytokines (68). Thus, they employ this pro-
cess now termed constitutive exocytosis where the cells contain
a pool of constitutively transcribed cytokine mRNA that is not
translated. Upon cellular stimulation, cytokine mRNAs are
“activated”/disinhibited and rapidly translated to produce cyto-
kines that can be detected in the Golgi apparatus within 20 min
and released within 1 h (69). Based on our results that increased
TNFa can occur in 1 h, the mRNA of TNFa is not increased,
and the membrane form TNFa was newly synthesized after
activation, we believe that TNFa secretion is mediated by disin-
hibition of previously synthesized mRNAwhere it can be trans-
lationally activated. Through this process, TNFa can be quickly
synthesized from existing mRNA and trafficked through the
Golgi apparatus for secretion.
Although the ability of 2-12(S)-HETE-lysophospholipids and
12(S)-HETE to initiate cellular signaling is described here, the
receptor(s) that mediate the downstream processes resulting in
increased TNFa synthesis and secretion remains to be discov-
ered. It has been suggested that G protein–coupled receptor 31
(GPR31) is a potential target of 12(S)-HETE. In previous work,
Honn et al. (70) identified GPR31 as the receptor for 12(S)-
HETE and demonstrated that the membrane fractions from
cells expressing GPR31 have high affinity binding sites for 12
(S)-HETE. Zhang et al. (74) suggest that GPR31 mediated the
hepatic ischemia-reperfusion injury caused by 12-lipoxygenase
and 12(S)-HETE. Accordingly, the observed effects likely ema-
nate through the GPR31 receptor, but other contributing
mechanisms remain possible. Collectively, these results dem-
onstrate the cellular signaling potential of 12(S)-HETE-lyso-
phospholipids and 12(S)-HETE as assessed by the induced
release of TNFa from human monocytic cells and reveal a pre-
viously uncharacterized role of 12(S)-HETE-lysophospholipids
and 12(S)-HETE in promoting inflammatory responses.
Experimental procedures
Materials
Plasmenyl-SAPE and plasmenyl-SAPC were obtained from
Avanti Polar Lipids (Alabaster, AL). Kinetex 5 mM EVO C18
column (2503 4.6 mm) and Kinetex 2.7 mM EVO C18 column
(1503 2.1 mm) were purchased from Phenomenex (Torrance,
CA). Oxidized fatty acids (HETEs and EETs), LDH cytotoxicity
assay kit, and AMP1 MaxSpec Kit were purchased from Cay-
man Chemical (Ann Arbor, MI). Human TNFa uncoated
ELISA kit, Pierce BCA protein assay kit, Halt protease/phos-
phatase inhibitor mixture, NuPAGE LDS sample buffer, Novex
WedgeWell Tris glycine precast gel, horseradish peroxidase-
linked anti-mouse IgG antibody, TRIzol reagent, Powerup
SYBR green master mix, SuperScript III First-Strand Synthesis
SuperMix, and 0.45 mM PVDF membrane were purchased
from ThermoFisher Scientific. Phospho-NF-kB p65 (Ser-536)
(93H1) rabbit mAb, phospho-IkBa rabbit mAb, TNFa rabbit
mAb, and horseradish peroxidase-linked anti-rabbit IgG anti-
body were purchased from Cell Signaling Technologies.
b-Tubulin mouse antibody was purchased from Santa Cruz.
Human proinflammatory cytokines MultiAnalyte ELISA Array
Figure 9. Synthesis of 2-12(S)-HETE-lysophospolipids and 12(S)-HETE. 2-Arachidonoyl-lysophospholipids are generated by PLA1-mediated hydrolysis of
phospholipids or by cytochrome c- catalyzed oxidative cleavage of plasmalogens. 2-Arachidonoyl-lysophospholipids can be oxidized by 12-LOX, generating
2-12(S)-HETE-lysophospholipids. Nonesterified 12(S)-HETE is synthesized by sequential PLA2-catalyzed hydrolysis of arachidonoyl-phospholipids and 12-LOX
catalyzed oxidation of the released arachidonic acid (AA).
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Kit was purchased from Qiagen. LC–MS grade acetonitrile and
water were obtained from Fisher Scientific (Pittsburgh, PA).
LC–MS grade methanol and isopropyl alcohol were purchased
from Burdick & Jackson (Muskegon, MI). HPLC grade metha-
nol and acetonitrile were purchased from Fisher Scientific
(Pittsburgh, PA). RPMI 1640 media and fetal bovine serum
were purchased from ThermoFisher Scientific. The THP-1 cell
line was purchased from American Type Culture Collection.
All other chemicals were purchased from SigmaAldrich.
General animal studies
Animal protocols were conducted in strict accordance with
the National Institutes of Health guidelines for humane treat-
ment of animals and were reviewed and approved by the Ani-
mal Studies Committee ofWashington University.
Activation of THP-1 cells by oxidized lipid agonists
THP-1 cells were grown in suspension in RPMI 1640 media
supplemented with 10% fetal bovine serum, 100 units/ml of
penicillin, 100 mg/ml of streptomycin, and 50 mM 2-mercapto-
ethanol. The cells were cultured in Corning T75 nontreated
flasks (431464U) in an upright position under a 5% CO2 atmos-
phere at 37 °C. The cells were routinely split at a 1:2 ratio when
the cell density reached 6 3 105 cells/ml. When subculturing
the cells, the cell suspension in growth media was centrifuged
at 2503 g for 7 min. The supernatant was then discarded, and
the cell pellet was resuspended in fresh growthmedia.
For experiments examining activation by various lipid ago-
nists, THP-1 cells in suspension were centrifuged at 2503 g for
7 min prior to resuspending the cell pellet in serum-free RPMI
1640 media without supplements and incubated for 4 h at 37 °C
under a 5% CO2 atmosphere. After serum starvation, the cell
suspension was centrifuged again at 250 3 g for 7 min and
resuspended in fresh serum free RPMI 1640 media without
supplements. The cell suspension was then dispensed into test
tubes containing DMSO stock solutions of each lipid agonist or
DMSO vehicle alone (0.1%, v/v). After adding the cell suspen-
sion, the test tubes were gently shaken while being incubated
for the indicated times at 37 °C under a 5% CO2 atmosphere. At
the end of the incubation period, the test tubes were gently
shaken again to thoroughly mix the media prior to centrifuga-
tion at 250 3 g for 3 min. An aliquot of the resultant superna-
tant (100 ml) from each separate sample was transferred to a 96-
well–plate coated with a capture antibody for ELISA analysis.
ELISA analysis of cytokines
ELISA to quantify specific cytokines were performed as
described by the manufacturer. Briefly, the capture antibody
was diluted in coating buffer, and 100 ml of capture antibody so-
lution was added to each well of a high binding 96-well–plate.
The plate was incubated at 4 °C overnight and then washed
three times with washing buffer (PBS, pH 7.4, 0.05% Tween-
20). Blocking solution (200 ml) was added to each well and incu-
bated at room temperature for 1 h. After aspiration of the
blocking solution, the wells were then washed once prior to
addition of 100 ml of either test sample or cytokine standard.
The plate was then sealed with a plate cover and incubated at
4 °C overnight. After removal of the well contents by aspiration,
the wells were washed three times. Next, the diluted biotin-
conjugated detection antibody (100 ml) was added and the plate
was incubated at room temperature for 1 h. The contents of the
wells were aspirated, and plate wells were then washed three
times. Avidin-conjugated horseradish peroxidase (100 ml) was
next added and the plate was then incubated at room tempera-
ture for 40 min. Contents of the wells were then aspirated, and
the plate was washed seven times. Following the addition of tet-
ramethylbenzidine substrate (100 ml) and incubation at room
temperature for 15 min, 1 M phosphoric acid (50 ml) was added
to terminate the reaction prior to measurement of the absorb-
ance at 450 nm.
Western blotting analysis
THP-1 cells (2 3 106 cells) were incubated with individual
lipid agonists as described under “Activation of THP-1 cells by
lipid agonists.”After incubation for the indicated times, the cell
suspension was centrifuged at 2503 g for 3 min. The superna-
tant was carefully aspirated to avoid disturbing the cell pellet.
The cell pellet was then suspended in 200 ml of cell lysis buffer
(50mMTris-HCl, 150mMNaCl, 1%Nonidet P-40, pH 7.4) con-
taining 13HaltTM protease and phosphatase inhibitor mixture
(Thermo Scientific). The cell lysate was sonicated with a probe
sonicator at 53 1 s (30% power) and centrifuged at 30003 g for
3 min. The supernatant was collected, and the protein content
was assayed by a BCA method as described in manufacturer’s
manual (PierceTM BCA protein assay kit, Thermo Scientific).
30 mg of protein of each sample was mixed with 12 ml of 43
NuPAGETM LDS sample buffer (Thermo Scientific) and 5 ml of
1 M DTT. The sample mixture was boiled for 3 min prior to
loading onto an SDS-PAGE gel. After running the gel, the sepa-
rated proteins were transferred to a 0.45 mM PVDF membrane
by electroelution. The membrane was then briefly washed with
TBS containing 0.1% Tween 20 (TBST buffer) and incubated
with blocking buffer (5% nonfat dry milk in TBST buffer) for 1
h. After blocking, the membrane was washed 33 10 min in
TBST buffer and incubated with a primary antibody (1:1000
dilution of the primary antibody in TBST buffer containing 2%
BSA) for 1 h. After incubating with the primary antibody, the
membrane was washed 33 10 min with TBST buffer and incu-
bated with a horseradish peroxidase-conjugated secondary
antibody (1:2000 dilution of antibody in TBST buffer contain-
ing 5% nonfat dry milk) for 40 min. Themembrane was washed
43 10 min with TBST buffer, incubated with ECL substrate
and exposed to X-ray film. For some experiments, immunoblot
band intensities were quantified by densitometry using a Kodak
Image Station with 2D software.
LDH cytotoxicity assay
The LDH assay was performed according to manufacturer’s
instructions. Briefly, 100 ml of cell culture media from each
sample was added to a 96-well–plate. For the positive control
sample, THP-1 cells were incubated in RPMI 1640 media con-
taining 1% Triton X-100 for 1 h. 100 ml of LDH reaction reagent
(NAD1, lactic acid, iodonitrotetrazolium, and diaphorase) was
added into each well and the 96-well–plate was incubated at
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37 °C for 30 min. The absorbance at 490 nm (A490) was read
with a plate reader. The cytotoxicity was calculated as (sample
A490 – control A490)/(positive control A490 – control A490).
Quantitative RT-PCR
qRT-PCR was performed as described previously (71).
Briefly, total RNA was extracted using TRIzol reagent. cDNA
was synthesized using Super-Script III First-Strand Synthesis
SuperMix. The resultant cDNA was amplified by RT-PCR
(Applied Biosystems) using Powerup SYBR Green master mix
and primers (TNFa and GAPDH) purchased from IDT. The







Expression and purification of recombinant human 12-LOX
100 ml of Sf9 cells (cultured in suspension at 1.23 106 cells/
ml) were infected with baculovirus (multiplicity of infection =
4) encoding recombinant human N-terminal-(His)6-12-LOX
and incubated for 48 h at 27°C. Harvested cells were centri-
fuged at 2503 g for 10min and washed once with ice-cold PBS.
The cell pellet was then resuspended in 2 ml of ice-cold 0.13
PBS and incubated on ice for 5 min. Next, 2 ml of equilibration
buffer (23 PBS containing 10 mM imidazole) containing 40 ml
of 0.1 M phenylmethylsulfonyl fluoride and 2 ml of 10 mg/ml of
leupeptin were added, vortexed, and the mixture was initially
sonicated with 203 1 s pulses at 50% power (Sonics VibraCell
sonicator). Following the addition of 10 ml of DNase I and 40ml
of 20% Tween-20, the cell lysate was again sonicated with 103
1-s pulses at 50% power and incubated on ice for 5 min. The
lysate was centrifuged at 15,0003 g for 15 min and the result-
ant supernatant (3.6 ml) was collected and mixed with an equal
volume of 33 PBS prior to loading onto a 1-ml HisPur nickel-
nitrilotriacetic acid column previously equilibrated with 20 ml
of equilibration buffer. The column was then washed with 20
ml of wash buffer (PBSwith 25mM imidazole) and the recombi-
nant human 12-lipoxygenase was eluted with elution buffer
(23 PBS with 200 mM imidazole). The eluent containing 12-li-
poxygenase was mixed with an equal volume of 40% glycerol
containing 10 mM FeCl2 prior to being flash frozen in liquid
nitrogen and stored at280 °C.
Synthesis and purification of 12(S)-HETE-lysophospholipids
2-Arachidonoyl lysophosphatidylcholine (2-AA-LPC) and 2-
arachidonoyl-lysophosphatidylethanolamine (2-AA-LPE) were
synthesized by incubating 1-(1Z-octadecenyl)-2-arachidonoyl-
sn-glycero-3-phosphocholine or 1-(1Z-octadecenyl)-2-arachi-
donoyl-sn-glycero-3-phosphoethanolamine, respectively, in
methanol/water (9:1, v/v) containing H2SO4 (0.4 N) at 70 °C for
5 min. 2-AA-lysophospholipids extracted from the acidic hy-
drolysis reaction were purified by RP-HPLC. A linear gradient
was used as follows using a flow rate of 1 ml/min: 0 min, 70% A
(acetonitrile, methanol, 10 mM ammonium acetate buffer,
2:1:1), 0% B (methanol), 30% C (water); 2 min, 70% A, 0% B,
30% C; 15 min, 100% A; 25 min, 100% A; 25.1 min, 100% B; 35
min, 100% B; 35.1 min, 70% A, 0% B, 30% C; 45 min, 70% A, 0%
B, 30% C. Purified 2-AA-lysophospholipids were resuspended
in reaction buffer (50 mM Tris-HCl, 100 mM NaCl, 0.5 mM
EDTA, pH 7.0) by vortexing and sonication (15 pulses3 1 s) at
a final concentration of 100 mM. Purified recombinant human
12-lipoxygenase was added to 1 ml of substrate at a final con-
centration of 50 mg of 12-LOX/ml and incubated at 37 °C for 30
min. The reaction was quenched by adding 2 ml of chloroform/
methanol (1:1) containing 0.1% acetic acid. The extractionmix-
ture was vigorously vortexed and then centrifuged at 1000 3 g
for 10 min. The chloroform phase was collected, and the
aqueous phase was re-extracted with 1 ml of chloroform.
The chloroform phases were combined and dried under a
nitrogen stream. The 12-HpETE-lysophospholipids gener-
ated by recombinant 12-LOX were then purified using
reversed-phase HPLC. To prepare 12-HETE-lysophospholi-
pids, 100 ml of 1 mg of triphenylphosphine/ml of methanol
(to reduce remaining hydroperoxyl groups to their hydroxyl
derivatives) was added to the dried 12-HpETE-lysophos-
pholipid products prior to rapid injection onto a RP-HPLC
column (Phenomenex Kinetex EVO C18 column (5 mM, 250
mm 3 4.6 mm)) for purification. A linear gradient was used
as follows using a flow rate of 1 ml/min: 0 min, 70% A (aceto-
nitrile, methanol, 10 mM ammonium acetate buffer, 2:1:1),
0% B (methanol), 30% C (water); 2 min, 70% A, 0% B, 30% C;
15 min, 100% A; 25 min, 100% A; 25.1 min, 100% B; 35 min,
100% B; 35.1 min, 70% A, 0% B, 30% C; 45 min, 70% A, 0% B,
30% C. Fractions containing 12(S)-HETE-lysophospholipids
were collected and dried under nitrogen flow. Chloroform/
methanol/water (1:1:1, final v/v/v) was added to the dried
products and vortexed. The chloroform phase was collected
and dried under nitrogen flow. The resulting products were
purged with nitrogen and stored at280 °C.
Platelet isolation and activation
Murine blood was obtained by intracardiac puncture of eu-
thanized mice. Approximately 0.8 ml of blood was drawn into a
syringe containing 0.15 ml of 3.8% sodium citrate to prevent
platelet activation. The blood was then centrifuged at 150 3 g
for 10 min and the platelet-rich plasma was subsequently cen-
trifuged at 2003 g for 5 min to remove residual red blood cells.
The purified platelet-rich plasma was centrifuged at 1500 3 g
for 10 min and the supernatant was discarded. The platelet pel-
let was then resuspended in Tyrode’s solution at room temper-
ature and used within 20 min of preparation. The platelet pro-
tein concentration was measured using a Bradford protein
assay (Bio-Rad). Platelets were activated by 20 mg/ml of mouse
thrombin and incubated at 37 °C for 15 min. The reactions
were terminated by the addition of chloroform/methanol (1:1,
v/v) and vortexed. The chloroform layer was collected and
dried under a nitrogen stream. The dried residue was re-dis-
solved in water/methanol (1:4) and resolved on a Kinetex EVO
C18 column (4.63 250 mm). A linear gradient was used as fol-
lows with a flow rate of 1 ml/min: 0 min, 60% A (acetonitrile/
methanol/water 2:1:1), 0% B (methanol), 40% C (2 mM potas-
sium phosphate buffer pH 7.2); 5 min, 60% A, 0% B, 40% C; 25
min, 100% A; 26 min, 100% B; 40 min, 100% B. From 7 to 21
min, eluents were collected every 2 min. Each eluent fraction
was dried under a stream of nitrogen and re-dissolved in 200 ml
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of chloroform/methanol (1:1). 10 ml of each fraction was ali-
quoted into glass test tubes in 4 replicates. The solvent was
dried by nitrogen stream and 1 ml of THP-1 cells suspension
(1 3 106 cells/ml) in RPMI 1640 media was added. The test
tubes were gently shaken and incubated at 37 °C under a 5%
CO2 atmosphere for 1 h. After 1 h incubation, the samples were
centrifuged at 2003 g for 3 min and TNFa in the supernatant
wasmeasured by ELISA as described above.
AMPP derivatization of oxidized fatty acids and LC–MS/MS
analysis
AMPP derivatization was performed using AMP1MaxSpec
Kit as described by Gelb and co-workers (72). In brief, 20 ml of
cold acetonitrile/N,N-dimethylformamide (4:1, v/v) was added
to the dried residue. The sample tube was vortexed, then 20 ml
of cold 640 mM N-(3-dimethylaminopropyl)-N’-ethylcarbodii-
mide in water, 10ml of 20mM 1-hydroxybenzotriazole in aceto-
nitrile/dimethylformamide (99:1, v/v), and 30 ml of AMPP in
acetonitrile were added and vortexed. After 30 min incubation
at 60 °C, the sample was cooled to room temperature and sub-
jected to LC–MS/MS analysis as previously described (73).
Briefly, LC–MS/MS analysis was performed using an LTQ
Orbitrap mass spectrometer connected to a Waters Acquity
UPLC system. Lipids were separated using a C18 reversed
phase column (Kinetex EVO C18, 2.7 mM, 150 3 2.1 mm) at
22 °C with a flow rate of 200ml/min. A linear gradient of solvent
A (10 mM ammonium acetate and 0.1% acetic acid (v/v) in
water) and solvent B (acetonitrile) were used as follows: 0 min,
25% B; 5 min, 25% B; 20 min, 95% B; 25 min, 95% B; 25.1 min,
25% B; 35 min, 25% B. The autosampler tray temperature was
set at 4 °C. The spray voltage in electrospray ionization source
was 4.1 kV. The sheath gas flow rate was 40 (arbitrary unit).
The capillary temperature was 270 °C. In MS/MS analysis, the
CID collision energy is 30, and the isolation width is 3 Th.
Statistical analyses
Results are expressed as mean6 S.D.
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